摘要
冠状病毒(CoVs)是普遍一类感染人和动物的包膜RNA病毒,其特点是传播性强,致病性高,可引起人类和动物严重的临床症状及死亡。特异性药物的研发是控制冠状病毒感染的有效途径。膜融合过程是病毒进入靶细胞的关键步骤,也是当前特异性药物的热门靶点。目前动物类冠状病毒的膜融合特异性治疗药物仍处于研发阶段,而人源冠状病毒已有部分特异性药物用于临床。这类药物主要有肽类、小分子类和蛋白质类,同时一些提高药物抑制效力的方法正在积极开发中。该综述介绍了针对冠状病毒膜融合过程中各个靶点不同类型的抑制剂,并讨论了其优缺点及未来展望,以期为冠状病毒的治疗和控制提供参考。
Coronaviruses are a type of enveloped RNA viruses that commonly infect humans and animals.They are known for their high transmissibility and pathogenicity,and can cause severe clinical symptoms and death.Developing specific medications is an effective strategy for controling coronavirus infection.The membrane fusion process plays a crucial role in the viral entry into target cells,and it is also a common target for specific medications.Drugs specifically targeting membrane fusion in animal coronaviruses are still in the research and development phase,while some drugs for human coronaviruses are already in clinical use.These medications primarily consist of peptides,small molecule and proteins,and some methods to improve the inhibitory effect of drugs are being actively developed.This review introduces various types of inhibitors that target different stages of the membrane fusion process in coronavirus,discussing their advantages,disadvantages and future potential to provide reference for the treatment and control of coronavirus.
作者
伍歆蕊
郭钟蔚
黄勇
崔敏
夏静
WU Xinrui;GUO Zhongwei;HUANG Yong;CUI Min;XIA Jing(College of Veterinary Medicine,Sichuan Agricultural University,Chengdu 611130,China;Key Laboratory of Agricultural Bioinformatics,Ministry of Education,Sichuan Agricultural University,Chengdu 611130,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2024年第10期1810-1820,共11页
Chinese Journal of Cell Biology
基金
四川省自然科学基金青年项目(批准号:24NSFSC7670、24NSFSC7764)
国家自然科学基金青年项目(批准号:32302906)
四川省区域创新合作项目(批准号:24QYCX0512)
国家现代农业产业技术体系四川鸡创新团队建设项目(批准号:SCCXTD-2024-24)资助的课题。
关键词
冠状病毒
膜融合抑制剂
肽
小分子
蛋白质
coronavirus
membrane fusion inhibitor
peptide
small molecules
protein
